The overall goals of the proposed work continue to be (i) the development of efficient methods for genetically modifying hematopoietic stem cells, (ii) the development of suitable methods for obtaining the appropriate in vivo expression of transferred genes, and (iii) the development of experimental model systems useful for understanding the control of hematopoiesis and for assessing the feasibility of genetic therapies for diseases affecting the hematopoietic system. The work currently proposed focuses in a major way upon the use of purified murine hematopoietic stem cells, rather than unfractionated bone marrow cells, as targets for gene transfer. An important component of the proposed work involves the physical and functional characterization of purified hematopoietic stem cells, with a particular emphasis upon understanding the functional properties of different hematopoietic cell populations that are important either for efficient genetic modification of stem cells or for the successful engraftment of lethally irradiated recipients with genetically modified cells. The proposed gene expression studies focus primarily upon features of retrovirus vector design and features of the inserted sequences themselves which influence the expression of recombinant retroviral genomes in vivo. An important new goal of this research program is to determine the feasibility of using homologous recombination techniques to 'repair' defective genes present in hematopoietic stem cells.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL037569-07
Application #
3353350
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1986-12-01
Project End
1995-11-30
Budget Start
1992-12-01
Budget End
1993-11-30
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
076580745
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Goodell, M A; Brose, K; Paradis, G et al. (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183:1797-806
Sadelain, M; Wang, C H; Antoniou, M et al. (1995) Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proc Natl Acad Sci U S A 92:6728-32
Riviere, I; Brose, K; Mulligan, R C (1995) Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A 92:6733-7
Karaplis, A C; Luz, A; Glowacki, J et al. (1994) Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277-89
Dranoff, G; Crawford, A D; Sadelain, M et al. (1994) Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264:713-6
Silver, D P; Spanopoulou, E; Mulligan, R C et al. (1993) Dispensable sequence motifs in the RAG-1 and RAG-2 genes for plasmid V(D)J recombination. Proc Natl Acad Sci U S A 90:6100-4
Spain, L M; Mulligan, R C (1992) Purification and characterization of retrovirally transduced hematopoietic stem cells. Proc Natl Acad Sci U S A 89:3790-4
Tybulewicz, V L; Crawford, C E; Jackson, P K et al. (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-63
Collins, M K; Malde, P; Miyajima, A et al. (1990) Evidence that the level of the p55 component of the interleukin (IL) 2 receptor can control IL 2 responsiveness in a murine IL 3-dependent cell. Eur J Immunol 20:573-8
Stuhlmann, H; Jaenisch, R; Mulligan, R C (1989) Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance. Mol Cell Biol 9:100-8

Showing the most recent 10 out of 13 publications